Defibrotide for the Treatment of Severe COVID-19
Defibrotide for the Treatment of Severe COVID-19
Recruiting · NCT04652115 · Registry updated 2026-07-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Defibrotide for the Treatment of Severe COVID-19 | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Phase 2 | 2026-07-20 | NCT04652115 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Brigham and Women's Hospital | 378 |
| Jazz Pharmaceuticals | 60 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 3 |